Literature DB >> 22527855

Hepatosplenic αβ T-cell lymphoma associated with azathioprine therapy.

Armin Rashidi, Michael E Lee, Stephen I Fisher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22527855     DOI： 10.1007/s12185-012-1081-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  14 in total

1.  Hepatosplenic T-cell lymphoma of alphabeta lineage.

Authors:  S Kumar; C Lawlor; E S Jaffe
Journal:  Am J Surg Pathol       Date:  2001-07       Impact factor: 6.394

Review 2.  Hepatosplenic T-cell lymphoma and inflammatory bowel disease.

Authors:  Anne Thai; Thomas Prindiville
Journal:  J Crohns Colitis       Date:  2010-06-25       Impact factor: 9.071

3.  Allogeneic transplantation for hepatosplenic alphabeta T-cell lymphoma.

Authors:  M R Mansour; A Dogan; E C Morris; A Khwaja; D C Linch; S Mackinnon; K S Peggs
Journal:  Bone Marrow Transplant       Date:  2005-05       Impact factor: 5.483

4.  Hepatosplenic alphabeta T-cell lymphoma successfully treated with allogeneic bone marrow transplantation.

Authors:  T Machino; Y Okoshi; S Kaneko; N Obara; H Y Mukai; K Suzukawa; Y Hasegawa; Y Yamashita; N Mori; H Kojima; T Nagasawa
Journal:  Bone Marrow Transplant       Date:  2007-02-19       Impact factor: 5.483

5.  Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk.

Authors:  Deepak Parakkal; Humberto Sifuentes; Rumi Semer; Eli Daniel Ehrenpreis
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-11       Impact factor: 2.566

6.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

7.  Hepatosplenic alphabeta T cell lymphoma.

Authors:  Yuya Nagai; Kazuhiro Ikegame; Minako Mori; Daichi Inoue; Takaharu Kimura; Sonoko Shimoji; Katsuhiro Togami; Sumie Tabata; Masayuki Kurata; Yukihiro Imai; Akiko Matsushita; Kenichi Nagai; Hiroyasu Ogawa; Takayuki Takahashi
Journal:  Int J Clin Oncol       Date:  2010-03-10       Impact factor: 3.402

8.  Hepatosplenic αβ T-cell lymphoma with myelodysplastic syndrome.

Authors:  Tomoiku Takaku; Keisuke Miyazawa; Goro Sashida; Nahoko Shoji; Takashi Shimamoto; Noritake Yamaguchi; Yoshikazu Ito; Shigeo Nakamura; Kiyoshi Mukai; Kazuma Ohyashiki
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

9.  Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

Authors:  W R Macon; N B Levy; P J Kurtin; K E Salhany; M Y Elkhalifa; T T Casey; F E Craig; C L Vnencak-Jones; M L Gulley; J P Park; J B Cousar
Journal:  Am J Surg Pathol       Date:  2001-03       Impact factor: 6.394

10.  Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia.

Authors:  R Lai; L M Larratt; W Etches; S T Mortimer; L D Jewell; L Dabbagh; R W Coupland
Journal:  Am J Surg Pathol       Date:  2000-03       Impact factor: 6.394
View more
  3 in total

1.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review.

Authors:  Mariko Yabe; L Jeffrey Medeiros; Yahya Daneshbod; Masoud Davanlou; Carlos E Bueso-Ramos; Elisa J Moran; Ken H Young; Roberto N Miranda
Journal:  Ann Diagn Pathol       Date:  2016-10-18       Impact factor: 2.090

2.  Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction.

Authors:  Marianna Mavilia; Agnes McAuliffe; Safina Hafeez; Haleh Vaziri
Journal:  Clin J Gastroenterol       Date:  2018-05-15

3.  Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma.

Authors:  A Rashidi; A F Cashen
Journal:  Blood Cancer J       Date:  2015-06-05       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.